FDA To Assess Anemia Drug Risks In Kidney Patients

Law360, New York (October 15, 2010, 10:59 AM EDT) -- A U.S. Food and Drug Administration advisory panel will meet on Monday to evaluate chronic kidney disease patients' use of popular anemia drugs made by Johnson & Johnson and Amgen Inc. and consider possible labeling and dosage changes, in light of new concerns about the drugs' health risks.

The purpose of the meeting, according to a draft briefing memo released Thursday, is to seek the advice of committee members on the benefit risk profile of eythropoiesis-stimulating agents, based on recent clinical test results that showed the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.